Evidence map›Paper›PMID 40841221›Full record

ArticleBritish journal of anaesthesia2025

Targeting the contributors to vasorelaxation during vasoplegia from cardiopulmonary bypass.

Patrick M Wieruszewski, Jamel P Ortoleva

Abstract readEditorial
In one paragraph

Article in British journal of anaesthesia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Patrick M WieruszewskiDepartment of Anesthesiology, Mayo Clinic, Rochester, MN, USA; Department of Pharmacy, Mayo Clinic, Rochester, MN, USA. Electronic address: wieruszewski.patrick@mayo.edu.
Jamel P OrtolevaDepartment of Anesthesiology, Boston Medical Center, Boston, MA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vasoplegia, a syndrome of noncardiogenic, non-hypovolaemic vasodilatory hypotension is a common complication of cardiac surgery utilising cardiopulmonary bypass. Vasopressor-sparing strategies have been increasingly used in the management of vasoplegia to minimise the untoward ischaemic and arrhythmogenic effects of vasoconstrictors. A recent study found that hydroxocobalamin, a non-vasoconstricting modulator of nitric oxide pathways, provided a clinically meaningful vasopressor-sparing effect in the first 24 h of vasoplegia. We highlight the broad implications of hydroxocobalamin in the management of vasoplegia associated with on-pump cardiac surgery.

Indexed as

Cardiopulmonary BypassHydroxocobalaminVasodilationVasoplegiaHumansVasoconstrictor AgentsHydroxocobalaminVasoconstrictor Agentscardiopulmonary bypasshydroxocobalaminnitric oxideshocksystemic vascular resistancevasoplegia

Identifiers

PMID40841221
PMCPMC12674058

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.